Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-F extension study of benralizumab after prior benralizumab parent studies
MOH_2026-06-22_016891Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of benralizumab in eosinophilic asthma (EA) and eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by AstraZeneca. Primary endpoint: Long-term safety and tolerability. Started May 2026; status: recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on MOH_2026-06-22_016891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-22_016891.